Payment overview · 2025
General Payments
$244.99
12 reported records · 9 companies
Healthcare provider profile · identity verified
Mark Henry Pico, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLAGSTAFF, AZ · NPI 1629284211
Verified facts
What the public records show
CMS Open Payments records show Mark Henry Pico, MD received $244.99 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.27 | 31.9% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.02 | 13.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $26.78 | 10.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.81 | 10.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.68 | 10.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.89 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.58 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.45 | 5.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.51 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $244.99 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $60.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 89 |
| Lisinopril | Lisinopril | 244 | 83 |
| Losartan Potassium | Losartan Potassium | 225 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 56 |
| Omeprazole | Omeprazole | 152 | 52 |
| Trazodone Hcl | Trazodone Hcl | 144 | 39 |
| Simvastatin | Simvastatin | 138 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 42 |
| Famotidine | Famotidine | 126 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 38 |
| Gabapentin | Gabapentin | 117 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 39 |
| Eliquis | Apixaban | 100 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 32 |
| Metformin Hcl | Metformin Hcl | 97 | 28 |
| Alendronate Sodium | Alendronate Sodium | 94 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 50 |
| Furosemide | Furosemide | 64 | 23 |
| Sertraline Hcl | Sertraline Hcl | 64 | 19 |
| Carvedilol | Carvedilol | 62 | 17 |
| Ozempic | Semaglutide | 62 | 13 |
| Potassium Chloride | Potassium Chloride | 62 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 16 |
| Allopurinol | Allopurinol | 58 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Azithromycin | Azithromycin | 54 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 17 |
| Montelukast Sodium | Montelukast Sodium | 52 | 19 |
| Prednisone | Prednisone | 52 | 28 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Glipizide Er | Glipizide | 46 | 13 |
| Tramadol Hcl | Tramadol Hcl | 46 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Valacyclovir | Valacyclovir Hcl | 41 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 16 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Spironolactone | Spironolactone | 31 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Daybue | Trofinetide | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $244.99 · 12 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, Flexitouch Plus, MOUNJARO, Nimbl, PROLIA, QULIPTA, TRELEGY ELLIPTA, UBRELVY, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error